Technical analysis of Coeptis Therapeutics Holdings, Inc. (COEP): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology.
Price Performance
| 1 month | +0.00% |
| 3 months | +0.00% |
| Year-to-date | +15.09% |
| 1 year | +30.16% |
| 3 years | -17.75% |
| 5 years | -91.73% |
52-Week Range
| 52-week High | $21.41 |
| 52-week Low | $6.26 |
| Avg Volume (90d) | 61K |
Technical Indicators
| SMA 50 | $12.26 |
| SMA 200 | $13.58 |
| Beta | -0.43 |
| 30-day Volatility (annualised) | 80.7% |
| Price vs SMA 50 | +33.8% |
| Price vs SMA 200 | +20.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $15.22 | |
| 2025-11 | $18.73 | +23.1% |
| 2025-12 | $14.25 | -23.9% |
| 2026-01 | $13.86 | -2.7% |
| 2026-02 | $12.04 | -13.1% |
| 2026-03 | $11.22 | -6.8% |
| 2026-04 | $16.40 | +46.2% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | $0.10 | $672M |
| 2026-09-14 | $-0.00 | $3M |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
Price
| Price | $10.99 |
| Market Cap | $39M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.50 |
| EV / EBITDA | -5.28 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 4.16 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 7.84 |